Adami, Giovanni Jaleel, Ayesha Curtis, Jeffrey R Delzell, Elizabeth Chen, Rui Yun, Huifeng Daigle, Shanette Arora, Tarun Danila, Maria I Wright, Nicole C
...
Published in
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Adverse events related to long-term use of bisphosphonates have raised interest in temporary drug discontinuation. Trends in bisphosphonate discontinuation and restart, as well factors associated with these decisions, are not fully understood at a population level. We investigated temporal trends of bisphosphonate discontinuation from 2010 to 2015 ...
Mori, Takahiro Crandall, Carolyn J Ganz, David A
Published in
JBMR Plus
Teriparatide, currently only available in brand form in the United States, is a costly drug approved for the treatment of postmenopausal osteoporotic women who are at high risk of fracture. Because market exclusivity for brand teriparatide expired in August 2019 in the US, we sought to understand the potential health economic impact of the availabi...
Mori, Takahiro Crandall, Carolyn J Ganz, David A
Teriparatide, currently only available in brand form in the United States, is a costly drug approved for the treatment of postmenopausal osteoporotic women who are at high risk of fracture. Because market exclusivity for brand teriparatide expired in August 2019 in the US, we sought to understand the potential health economic impact of the availabi...
Constantino, Christopher S. Krzak, Joseph J. Fial, Alissa V. Kruger, Karen M. Rammer, Jacob R. Radmanovic, Katarina Smith, Peter A. Harris, Gerald F.
Published in
JBMR Plus
Osteogenesis imperfecta (OI) is a rare genetic connective tissue disorder that results in bone fragility and deformity. Management is multi‐disciplinary. Although pharmacologic intervention with bisphosphonates (BP) is a standard of care for individuals with severe OI, no consensus or reviews were found that focus on the effects of bisphosphonates ...
Iseri, Ken Watanabe, Makoto Yoshikawa, Hisako Mitsui, Hisao Endo, Teruhiko Yamamoto, Yuichiro Iyoda, Masayuki Ryu, Kakei Inaba, Taro Shibata, Takanori
...
Published in
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Mineral and bone disorders including osteoporosis are common in dialysis patients and contribute to increased morbimortality. However, whether denosumab and alendronate are effective and safe treatments in hemodialysis patients is not known. Thus, we conducted a prospective, three-center study of 48 hemodialysis patients who were diagnosed as havin...
Duckworth, Andrew D McQueen, Margaret M Tuck, Christopher E Tobias, Jonathan H Wilkinson, Jeremy Mark Biant, Leela C Pulford, Elizabeth Claire Aldridge, Stephen Edwards, Claire Roberts, Chris P
...
Published in
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
There is a concern that bisphosphonates may impair fracture healing because of their inhibitory effects on bone turnover. Here we evaluated the effects of early bisphosphonate therapy on fracture healing and functional outcome following a fracture of the distal radius. The fracture and bisphosphonates (FAB) trial was a double-blind, randomized, pla...
Rausch, V Schwarzer, A Dietrich, JW Kaisler, M Seybold, D Vollert, J Schildhauer, TA Maier, C
Osteoporosis remains a major health concern due to high incidence of fragility fractures followed by higher mortality and morbidity. Implementation of guidelines for diagnosis and treatment of osteoporosis is critically discussed internationally. Aim of this study was to evaluate implementation of these guidelines regarding diagnosis and therapy of...
Jin, A Cobb, JP Hansen, U Bhattacharya, R Reinhard, C Vo, N Atwood, R Li, J Abel, RL
Objectives Bisphosphonates (BP) are the first-line treatment for preventing fragility fractures. However, concern regarding the efficacy is growing because bisphosphonate is associated with over-suppression of remodelling and accumulation of microcracks. While DEXA scanning may show a gain in bone density the impact of this class of drug on mechani...
Genant, Harry K Engelke, Klaus Bolognese, Michael A Mautalen, Carlos Brown, Jacques P Recknor, Chris Goemaere, Stefan Fuerst, Thomas Yang, Yu-Ching Grauer, Andreas
...
Published in
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Romosozumab, a monoclonal antibody that binds sclerostin, has a dual effect on bone by increasing bone formation and reducing bone resorption, and thus has favorable effects in both aspects of bone volume regulation. In a phase 2 study, romosozumab increased areal BMD at the lumbar spine and total hip as measured by DXA compared with placebo, alend...
Anagnostis, Panagiotis Paschou, Stavroula A Mintziori, Gesthimani Ceausu, Iuliana Depypere, Herman Lambrinoudaki, Irene Mueck, Alfred Pérez-López, Faustino R Rees, Margaret Senturk, Levent M
...
Background: Bisphosphonates and denosumab are used extensively in the treatment of postmenopausal osteoporosis. Despite their proven efficacy in the reduction of vertebral and non-vertebral fractures, their optimal duration of use has not been determined. The occurrence of adverse effects, such as osteonecrosis of the jaw (ONJ) and atypical femoral...
